{
    "root": "36370286-cb1c-9104-e063-6394a90a9cf9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mirtazapine",
    "value": "20250528",
    "ingredients": [
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "2165RE0K14"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "MIRTAZAPINE",
            "code": "A051Q2099Q"
        }
    ],
    "indications": "mirtazapine tablets indicated treatment major depressive disorder ( mdd ) adults [ ( 14 ) ] .",
    "contraindications": "starting dose : 15 mg daily ; may increase maximum recommended dose 45 mg daily . ( 2.1 ) administer orally daily , preferably evening prior sleep . ( 2.1 ) reduce dose gradually discontinuing mirtazapine tablets . ( 2.6 , 5.14 )",
    "warningsAndPrecautions": "mirtazapine tablets , usp supplied : 30 mg tablets – reddish brown , biconvex , capsule shaped film coated tablets score line “ 0 ” “ 9 ” one side “ ” debossed side . ndc : 70518-0316-00 packaging : 30 1 blister pack store 25°c ( 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . protect light moisture . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "mirtazapine tablets contraindicated patients : taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.3 ) , ( 7 ) ] . known hypersensitivity mirtazapine ofthe excipients mirtazapine tablets . severe skin , including reaction eosinophilia systemic symptoms ( dress ) , stevens-johnson syndrome , bullous dermatitis , erythema multiforme toxic epidermal necrolysis reported following mirtazapine tablets [ ( 5.6 ) , ( 6.2 ) ] .",
    "indications_original": "Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults\n \n  [see\n  \n   Clinical Studies (14)].",
    "contraindications_original": "Starting dose: 15 mg once daily; may increase up to maximum recommended dose of 45 mg once daily. ( 2.1 ) Administer orally once daily, preferably in the evening prior to sleep. ( 2.1 ) Reduce dose gradually when discontinuing mirtazapine tablets. ( 2.6 , 5.14 )",
    "warningsAndPrecautions_original": "Mirtazapine tablets, USP are supplied as:\n                  30 mg Tablets – Reddish brown, biconvex, capsule shaped film coated tablets with a score line in between “0” and “9” on one side and “A” debossed on the other side.\n                  \n                  NDC: 70518-0316-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light and moisture.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Mirtazapine tablets are contraindicated in patients:\n                  \n                  \n                     Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [see\n   \n    Warnings and Precautions (5.3),\n   \n    Drug Interactions (7)].\n  \n   \n                     \n                     \n                        With a known hypersensitivity to mirtazapine or to any ofthe excipients in mirtazapine tablets. Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have been reported following the use of mirtazapine tablets\n  \n    [see\n   \n     Warnings and Precautions (5.6),\n   \n     Adverse Reactions (6.2)]."
}